The DOI matches its Crossref record; 207 of the 207 references it cites were found in a registry or an index.
Oxidatively Modified Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) and Alzheimer's Disease: Many Pathways to Neurodegeneration
Open accessAbstract
Recently, the oxidoreductase, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), has become a subject of interest as more and more studies reveal a surfeit of diverse GAPDH functions, extending beyond traditional aerobic metabolism of glucose. As a result of multiple isoforms and cellular locales, GAPDH is able to come in contact with a variety of small molecules, proteins, membranes, etc., that play important roles in normal and pathologic cell function. Specifically, GAPDH has been shown to interact with neurodegenerative disease-associated proteins, including the amyloid-beta protein precursor (AbetaPP). Studies from our laboratory have shown significant inhibition of GAPDH dehydrogenase activity in Alzheimer's disease (AD) brain due to oxidative modification. Although oxidative stress and damage is a common phenomenon in the AD brain, it would seem that inhibition of glycolytic enzyme activity is merely one avenue in which AD pathology affects neuronal cell development and survival, as oxidative modification can also impart a toxic gain-of-function to many proteins, including GAPDH. In this review, we examine the many functions of GAPDH with respect to AD brain; in particular, the apparent role(s) of GAPDH in AD-related apoptotic cell death is emphasized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–207 of 207
Tamaoka, A., Endoh, R., Shoji, S., Takahashi, H., Hirokawa, K., Teplow, D. B., Selkoe, D. J., & Mori, H. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00031-0 · Cited by 26
Yong-Hui, C. H. E. N., He, R.-Q., Ying, L. I. U., Liu, Y., & Xue, Z. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510233 · Cited by 26
Reiss, N. A., Oplatka, A., Hermon, J., & Naor, Z. (1996) · IUBMB Life · doi:10.1080/15216549600201833 · Cited by 25
Glutathione Conjugates Recognize the Rossmann Fold of Glyceraldehyde-3-phosphate Dehydrogenase
Puder, M., & Soberman, R. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.16.10936 · Cited by 20
Corbin, I. R., Gong, Y., Zhang, M., & Minuk, G. Y. (2002) · Cell Proliferation · doi:10.1046/j.1365-2184.2002.00236.x · Cited by 19
Arutyunov, D., & Muronetz, V. I. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02802-4 · Cited by 18
Identification of non-Alzheimer's disease tauopathies-related proteins by proteomic analysis
Yang, G., Wang, L., Zhu, M., & Xu, D. (2008) · Neurological Research · doi:10.1179/174313208x284124 · Cited by 10
Cited by
Smart micro/nanoparticles in stimulus-responsive drug/gene delivery systems
Karimi, M., Ghasemi, A., Sahandi Zangabad, P., Rahighi, R., Moosavi Basri, S. M., Mirshekari, H., Amiri, M., Shafaei Pishabad, Z., Aslani, A., Bozorgomid, M., et al. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00798d · Cited by 1,519
Enzyme-responsive nanoparticles for drug release and diagnostics
de la Rica, R., Aili, D., & Stevens, M. M. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.01.002 · Cited by 765
Enzyme-responsive nanomaterials for controlled drug delivery
Hu, Q., Katti, P. S., & Gu, Z. (2014) · Nanoscale · doi:10.1039/c4nr04249b · Cited by 668
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Butterfield, D. A., & Boyd-Kimball, D. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170543 · Cited by 403
Self-citation
Metadata
- Authors
- Butterfield, D. A., Hardas, S. S., & Lange, M. L. B.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2010-04-01
- Volume
- 20
- Issue
- 2
- Pages
- 369-393
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W2125155866
- Cited by
- 262
- References
- 207
- FWCI
- 9.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.